2024-09-15 - Analysis Report
##  MRK Stock Analysis Report

**Company:** Merck & Co., Inc. (MRK) is a leading pharmaceutical company known for its diverse portfolio of prescription medicines, vaccines, and animal health products. 

**1. Performance Comparison:**

* **Cumulative Return:** MRK has generated a cumulative return of 48.52% compared to 87.74% for the S&P 500 (VOO). This puts MRK's performance **39.22%** behind the benchmark. 
* **Relative Divergence:** The relative divergence of -39.22% represents MRK's performance relative to the S&P 500. Currently, it is **35.57%** below the maximum difference between the two returns.

**2. Recent Price Movements:**

* **Closing Price:** $115.25
* **5-Day Moving Average:** $115.71
* **20-Day Moving Average:** $116.07
* **60-Day Moving Average:** $120.87

The stock price is currently trading below all three moving averages, suggesting a **short-term downtrend**. 

**3. Technical Indicators:**

* **RSI:** 44.77 - This indicates a **neutral** level, suggesting neither overbought nor oversold conditions.
* **PPO:** 0.08 - This indicates a **weak bullish signal**, suggesting potential upward price movement.
* **Delta_Previous_Relative_Divergence:** -3.05 - The negative value indicates a **recent short-term downtrend**, suggesting a decline in MRK's performance relative to the S&P 500.
* **Expected_Return:** 12.4% - This represents the potential **maximum annualized return** over a 5-year period, based on current investment amount and market conditions.

**4. Recent Earnings and Outlook:**

| Date  | EPS      | Revenue         |
|-------|----------|-----------------|
| 2024-08-05 | 2.15     | $16.11B        |
| 2024-05-03 | 1.88     | $15.78B        |
| 2023-11-03 | 1.87     | $15.96B        |
| 2023-08-07 | -2.35    | $15.04B        |
| 2024-08-05 | -2.35    | $15.04B        |

The most recent earnings report (2024-08-05) showed an EPS of $2.15, exceeding analyst estimates of $1.97. Revenue also came in higher than expected at $16.11 billion. 

**5. Overall Analysis:**

* MRK's performance has lagged behind the S&P 500 over the past period. However, the recent earnings report shows positive momentum with exceeding analysts' expectations. 
* Technical indicators present a mixed picture, with neutral RSI and a weak bullish signal from the PPO.  However, the recent short-term downtrend and the stock price trading below all three moving averages indicate potential for further decline in the near future. 
* The expected return of 12.4% suggests a promising long-term growth potential. However, investors should consider the short-term risks associated with current market conditions and the potential for continued volatility in the pharmaceutical sector.

**6. Conclusion:**

MRK's recent earnings report is a positive sign, exceeding analysts' expectations and demonstrating potential for future growth. However, the stock's performance has been trailing the S&P 500, and technical indicators suggest potential for further decline in the near future. Investors should consider these factors and their own risk tolerance before making investment decisions. 
